**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 87835

**Manuscript Type:** CASE REPORT

**Renal pelvis sarcomatoid carcinoma with renal vein tumor thrombus: A case report and literature review**

Guan HY *et al.* Renal pelvis sarcomatoid carcinoma

Huai-Yong Guan, Jin Wang, Ji-Xue Wang, Qi-Hui Chen, Ji Lu, Liang He

**Huai-Yong Guan, Jin Wang, Ji-Xue Wang, Qi-Hui Chen, Ji Lu, Liang He,** Department of Urology, Jilin University First Hospital, Changchun 130000, Jilin Province, China

**Author contributions:** Guan HY and He L designed the case report; Guan HY, Wang J, and Wang JX admitted the patient and collected relevant information and materials; Chen QH, Lu J, and He L participated in patient surgical treatment; Guan HY and He L analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.

**Supported by** Science and Technology Development Program of Jilin Province, No. 2020122256JC and No. 20200201602JC.

**Corresponding author: Liang He, Doctor, Doctor,** Department of Urology, Jilin University First Hospital, No. 1 Xinmin Street, Changchun 130000, Jilin Province, China. lianghe9278@jlu.edu.cn

**Received:** August 30, 2023

**Revised:** October 6, 2023

**Accepted:** October 26, 2023

**Published online:** November 6, 2023

**Abstract**

BACKGROUND

Renal pelvis sarcomatoid carcinoma (RPSC) is a rare and aggressive malignancy whose diagnosis is difficult because radiological imaging results can lead to misclassification as a more common type of renal tumor. In addition, clinical management of patients with RPSC is difficult because of the limited efficacy of available treatments. In this study, we present a comprehensive description of a patient who presented with RPSC and a simultaneous renal vein tumor thrombus.

CASE SUMMARY

During April, 2020, a 64-year-old female presented with an isolated episode of hematuria accompanied by abdominal pain. Computed tomography (CT) and magnetic resonance imaging (MRI) showed a lesion in the right renal pelvis. We therefore performed a radical nephrectomy of the right kidney. The subsequent histopathological and immunological results verified the diagnosis of RPSC. Despite administration of 6 cycles of a gemcitabine-cisplatin regimen, the patient's condition progressively deteriorated, and she died about 15 mo after the nephrectomy.

CONCLUSION

We performed a comprehensive analysis of a patient with RPSC that included CT, MRI, immunohistochemistry, and genetic testing. The insights from our detailed analysis of this patient and our concomitant review of the literature may assist clinicians in their diagnosis and treatment of RPSC.

**Key Words:** Sarcomatoid carcinoma; Renal pelvis; Gene analysis; Literature review; Case report

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Guan HY, Wang J, Wang JX, Chen QH, Lu J, He L. Renal pelvis sarcomatoid carcinoma with renal vein tumor thrombus: A case report and literature review. *World J Clin Cases* 2023; 11(31): 7690-7698

**URL**: https://www.wjgnet.com/2307-8960/full/v11/i31/7690.htm

**DOI**: https://dx.doi.org/10.12998/wjcc.v11.i31.7690

**Core Tip:** Renal pelvis sarcomatoid carcinoma (RPSC) is an extremely rare tumor that is associated with a high mortality rate. We present a rare case of right RPSC with renal vein tumor thrombus, in which diagnosis was based on evidence from radiology, pathology, and analysis of tumor mutations. The specific genetic mutations in this patient’s tumor may provide insights into the invasive phenotype and pathogenesis of this cancer.

**INTRODUCTION**

Renal pelvis sarcomatoid carcinoma (RPSC) is a rare type of urinary tract malignancy[1]. This cancer has a low incidence, and it accounts for only about 0.3% of all urothelial carcinomas[2]. Since the initial description of this tumor by Fauci and colleagues in 1961, there have been fewer than 30 reported cases[3]. There are similar predisposing factors for RPSC and renal squamous cell carcinoma, including tobacco consumption, persistent irritation, chronic inflammation, and nephrolithiasis[4]. Surgery is the most efficacious and widely adopted treatment for patients with RPSC[5], and the major approaches are nephroureterectomy or nephrectomy. An accurate diagnosis of RPSC requires a comprehensive clinical assessment with histological and immunohistochemical analyses of the tumor[6].

Herein we present a patient with RPSC and describe the results from imaging, histochemistry, and genetics (Figure 1). We also provide a comprehensive review of the literature on this topic to consolidate all previous clinical findings on this cancer.

**CASE PRESENTATION**

***Chief complaints***

A 64-year-old female (weight: 60 kg, height: 165 cm) who presented in April, 2020 was assessed for a recent isolated episode of hematuria that was accompanied by abdominal pain.

***History of present illness***

During the past five months, the patient reported a decrease in body weight of about 5 kg.

***History of past illness***

The patient had a medical history of bilateral renal stones. Additionally, she received pharmaceutical management for hypertension for many years, and intermittently utilized nifedipine.

***Personal and family history***

The patient had no specific personal or family history of illnesses.

***Physical examination***

Upon admission, the patient's body temperature was 36.5°C, heart rate was 75 beats per min, respiratory rate was 19 breaths per min, blood pressure was 145/90 mmHg, and oxygen saturation (while breathing ambient air) was 99%. She also had mild tenderness in the right lumbar and abdominal regions.

***Laboratory examinations***

A urinalysis indicated the red blood cell count was 581.5/μL and the round epithelial cell count was 2.4/μL. An exfoliative cytology test indicated no atypical epithelial cells.

***Imaging examinations***

A conventional abdominal computed tomography (CT) scan (Figure 2) demonstrated irregular enlargement of the right kidney, indicative of a space-occupying lesion. The subsequent enhanced magnetic resonance imaging (MRI) results, which used a gadolinium-based contrast agent (Figure 3), revealed a distinctive clumpy and abnormal signal in the right renal pelvis that had dimensions of 7.9 cm × 6.4 cm × 7.4 cm (Figure 4). The tumor had uniformly low signal intensity in the T1-weighted phase, and slightly elevated mixed signal intensity in the T2-weighted phase. We also identified multiple enlarged lymph nodes in the retroperitoneal region, raising a concern of metastasis. After nephrectomy, immunohistochemical analysis of tumor samples indicated positive staining for Ki-67 (70%), CKpan, 34β12, p63, GATA3, and vimentin, but negative staining for CK7 and PAX8 (Figure 5). There was also evidence from the MRI of cancerous infiltration in the renal sinus, renal parenchyma, and vasculature, and a cancerous thrombus in the right renal vein.

A genetic analysis of the tumor tissue showed mutations in the *ELF*, *LTK*, *NOTCH2*, *REL*, and *ZFHX3* genes (Table 1). However, there were no mutations in genes that have known relationships with hereditary tumors. Furthermore, the gene analysis yielded no specific drug targets that could be used for pharmacological intervention.

**FINAL DIAGNOSIS**

A postoperative pathological assessment confirmed that the tumor was RPSC, and had dimensions of 9.0 cm × 8.0 cm × 5.5 cm. Based on standard staging criteria[7], we classified the tumor as T3N1Mx.

**TREATMENT**

Following a thorough preoperative evaluation, the patient underwent right renal nephrectomy. Two months later, she opted for conventional systemic chemotherapy. This treatment commenced in July, 2020, and consisted of 6 cycles (21 d per cycle) of gemcitabine-cisplatin (GC).

**OUTCOME AND FOLLOW-UP**

The patient experienced a favorable postoperative recovery and was discharged after 6 d. However, the subsequent GC chemotherapy was ineffective and the patient died about 15 mo after the surgery.

**DISCUSSION**

Upper-tract urothelial cancer is the most prevalent malignancy affecting the renal pelvis, but only accounts for 5% to 10% of all urothelial cancers. Squamous cell carcinoma and adenocarcinoma are the second and third most common types of renal pelvis malignancies[8]. RPSC is a very rare and aggressive type of urothelial carcinoma, and there have only been descriptions of fewer than 30 cases (Table 2). A retrospective analysis of these previous cases indicated the onset of RPSC typically occurs in patients more than 50-years-old, and the sex ratio is about 4 or 5 males to 12 females[2] (Table 2). The apparent risk factors for RPSC are tobacco smoking, previous genital tract irradiation, inflammation, and nephrolithiasis[9]. Our 64-year-old female patient had no history of smoking or genital tract irradiation, but she did have a history of nephrolithiasis. Renal stones can possibly lead to provocation of squamous cell carcinoma in the renal pelvis[10], so we hypothesize that renal stones could have contributed to the progression of RPSC in our patient. The origin of RPSC remains controversial. The monoclonal theory posits that carcinomatous and sarcomatous tumor cells arise from pluripotent stem cells, whereas the multiclonal theory proposes that sarcomatoid carcinoma is a “collision tumor” that results from derivatives of distinct epithelial and mesenchymal stem cells[11].

The clinical manifestations of RPSC are variable. Previous studies reported that hematuria was the most frequently reported symptom. Localized or non-specific pain was reported as the second most prevalent symptom[5], and this can escalate to severe pain. In rare cases, the presence of a renal pelvis abscess could indicate RPSC[6,12]. These patients also frequently experience initial symptoms indicative of an inflammatory infection. In situations where RPSC coincides with a renal abscess, the abscess frequently obscures the symptoms of the tumor, leading to a delayed or missed diagnosis.

Imaging examinations are crucial for the preoperative assessment of tumors in the renal pelvis. CT and MRI scans can be used to determine tumor size, metastasis, and the presence of a tumor thrombus (Figures 2 and 3). Mild to moderate heterogeneous enhancement occurs when using a contrast agent, but distinguishing RPSC from other renal pelvis tumors remains challenging. Immunohistochemistry results are therefore essential for the diagnosis of RPSC. The sarcomatoid component of RPSC can coexist with other tumor types, including adenocarcinoma, small cell carcinoma, or squamous cell carcinoma. HE staining yields similar cellular morphologies for carcinosarcoma and sarcomatoid carcinoma (Figure 4), but RPSC has positive staining for Ki-67 (70%), CKpan, 34β12, p63, GATA3, and vimentin, while negative staining for PAX8 and CK7.

We also performed a comprehensive analysis of genetic alterations in the patient’s tumor, and identified mutations in the *ELF*, *LTK*, *NOTCH2*, *REL*, and *ZFHX3* genes (Table 1). The *ELF3* gene is a member of the E26 transformation-specific family of transcription factors, is located on chromosome 1q32.1, and encodes a protein of 371 amino acids[13]. Previous studies have implicated *ELF3* in various diseases, including cancers of the bladder, ovary, biliary tract, stomach, cervix, breast, prostate, lung, liver, and colon[14]. Studies of mutations in the *ELF3* gene demonstrated this gene functions as a tumor suppressor in certain cancers, although increased *ELF3* expression also occurs in other cancers[15]. *NOTCH2* is a member of the Notch receptor family that is overexpressed in many cancers, and is linked with distinctive oncogenic mechanisms[16]. *LTK* is in the anaplastic lymphoma kinase (*ALK*)/*LTK* subfamily, and increased expression of this gene is associated with metastasis in certain cancers[17].

Although our genetic testing confirmed that RPSC has a highly invasive and metastatic phenotype, the lack of effective targeted therapies accounts for the grim prognosis for most patients with this cancer. Only a limited number of these patients achieve survival beyond two years[1]. The unique characteristics of this tumor are likely responsible for the ineffectiveness of conventional chemotherapy and radiotherapy regimens. Surgical excision is the preferred initial procedure for treating RPSC[6], and subsequent radiotherapy can enhance local control when combined with cisplatin-based chemotherapy[18]. However, cisplatin-based chemotherapy is unfeasible in some patients due to a low estimated glomerular filtration rate and diminished renal function after nephrectomy[19]. Previous research has indicated heightened expression of the epidermal growth factor receptor (EGFR) on the surface of RPSC cells[20], so therapeutic strategies that target EGFR may have some potential. Other research found that RPSC cells had high expression of PDL1, suggesting that immunotherapy may be beneficial[21]. Our patient only survived 15 mo after surgery, despite use of GC-based chemotherapy. We hope that future studies which identify more effective treatments can prolong the survival times of these patients.

**CONCLUSION**

Given the rarity of RPSC, diagnosis is difficult and there are inadequate available treatments. In this study, we presented a new case of RPSC and conducted a comprehensive review of the most recent literature. We also performed immunohistochemical and genetic analyses of our patient. The indicators described herein may be useful in guiding future clinical interventions for the treatment of patients with RPSC.

**REFERENCES**

1 **Chen S**, Chen G, Xia D, Li J, Wang S, Shen B, Jin B. Sarcomatoid carcinoma of the renal pelvis: Experience of multiple cases over a ten-year period. *Oncol Lett* 2013; **6**: 513-516 [PMID: 24137357 DOI: 10.3892/ol.2013.1396]

2 **Tian X**, Zhao J, Wang Y, Xing N. Sarcomatoid carcinoma of the renal pelvis: A case report. *Oncol Lett* 2014; **8**: 1208-1210 [PMID: 25120689 DOI: 10.3892/ol.2014.2240]

3 **Fauci Pa Jr**, Therhag Hg, Davis Je. Carcinosarcoma of the renal pelvis. *J Urol* 1961; **85**: 897-902 [PMID: 13698330 DOI: 10.1016/S0022-5347(17)65448-X]

4 **Kivlin D**, Tong C, Friedlander J, Perosio P, Simhan J. Sarcomatoid Squamous Cell Carcinoma of the Renal Pelvis Masquerading as Emphysematous Pyelonephritis with Staghorn Calculus. *J Endourol Case Rep* 2016; **2**: 87-89 [PMID: 27579427 DOI: 10.1089/cren.2016.0047]

5 **Mantica G**, Benelli A, Ackermann H, Nxumalo Z, Solaiman A, Dotta F, van der Merwe A, Terrone C. Clinical and histopathological features of carcinosarcoma of the renal pelvis: a systematic review of a rare tumor. *Minerva Urol Nefrol* 2019; **71**: 121-126 [PMID: 30203938 DOI: 10.23736/S0393-2249.18.03192-2]

6 **Chu Y**, Ning H, Yin K, Chen T, Wu H, Wang D, Liu F, Zhao Z, Lv J. Case report: Sarcomatoid urothelial carcinoma of the renal pelvis masquerading as a renal abscess. *Front Oncol* 2023; **13**: 1055229 [PMID: 36756151 DOI: 10.3389/fonc.2023.1055229]

7 **Rouprêt M**, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, Gürses Andersson I, Liedberg F, Mariappan P, Hugh Mostafid A, Pradere B, van Rhijn BWG, Shariat SF, Rai BP, Soria F, Soukup V, Wood RG, Xylinas EN, Masson-Lecomte A, Gontero P. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. *Eur Urol* 2023; **84**: 49-64 [PMID: 36967359 DOI: 10.1016/j.eururo.2023.03.013]

8 **Masue N**, Hasegawa Y, Moriyama Y, Ikeda Y, Gotoh T, Deguchi T. Spontaneous disappearance of multiple lung metastases after nephroureterectomy from sarcomatoid carcinoma of the renal pelvis: a case report. *Int J Urol* 2007; **14**: 75-78 [PMID: 17199865 DOI: 10.1111/j.1442-2042.2006.01603.x]

9 **Gill-Samra S**, Brooks A, P'ng CH. Sarcomatoid carcinoma involving the renal pelvis and ureter with heterologous osteosarcomatous differentiation. *Pathology* 2012; **44**: 367-369 [PMID: 22544213 DOI: 10.1097/PAT.0b013e328353be4a]

10 **Vallejo EP**, Tejido Sánchez Á, Miranda Utrera N, Gómez Del Cañizo C. Massive Hydronephrosis, Countless Lithiasis and Upper Urinary Tract Carcinoma. *Urology* 2022; **165**: e7-e8 [PMID: 35413376 DOI: 10.1016/j.urology.2022.03.024]

11 **Rashid S**, Akhtar M. Sarcomatoid Variant of Urothelial Carcinoma of the Renal Pelvis with Inferior Vena Cava Tumour Thrombus: A Case Report and Literature Review. *Case Rep Pathol* 2018; **2018**: 1837510 [PMID: 29581908 DOI: 10.1155/2018/1837510]

12 **Terada T**. Multiple cytokeratin-negative malignant tumors composed only of rhabdoid cells in the renal pelvis: a sarcomatoid urothelial carcinoma? *Int J Clin Exp Pathol* 2013; **6**: 724-728 [PMID: 23573320]

13 **Luk IY**, Reehorst CM, Mariadason JM. ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer. *Molecules* 2018; **23** [PMID: 30200227 DOI: 10.3390/molecules23092191]

14 **Sarmah S**, Hawkins MR, Manikandan P, Farrell M, Marrs JA. Elf3 deficiency during zebrafish development alters extracellular matrix organization and disrupts tissue morphogenesis. *PLoS One* 2022; **17**: e0276255 [PMID: 36383615 DOI: 10.1371/journal.pone.0276255]

15 **Takaoka A**, Ishikawa T, Okazaki S, Watanabe S, Miya F, Tsunoda T, Kikuchi A, Yamauchi S, Matsuyama T, Tokunaga M, Uetake H, Kinugasa Y. ELF3 Overexpression as Prognostic Biomarker for Recurrence of Stage II Colorectal Cancer. *In Vivo* 2021; **35**: 191-201 [PMID: 33402466 DOI: 10.21873/invivo.12248]

16 **Xiu MX**, Liu YM. The role of oncogenic Notch2 signaling in cancer: a novel therapeutic target. *Am J Cancer Res* 2019; **9**: 837-854 [PMID: 31218097]

17 **Cooper AJ**, Sequist LV, Johnson TW, Lin JJ. LTK fusions: A new target emerges in non-small cell lung cancer. *Cancer Cell* 2022; **40**: 23-25 [PMID: 35016028 DOI: 10.1016/j.ccell.2021.12.012]

18 **Hall MC**, Womack JS, Roehrborn CG, Carmody T, Sagalowsky AI. Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. *J Urol* 1998; **160**: 703-706 [PMID: 9720526 DOI: 10.1016/S0022-5347(01)62763-0]

19 **Tafuri A**, Marchioni M, Cerrato C, Mari A, Tellini R, Odorizzi K, Veccia A, Amparore D, Shakir A, Carbonara U, Panunzio A, Trovato F, Catellani M, Janello LMI, Bianchi L, Novara G, Dal Moro F, Schiavina R, De Lorenzis E, Parma P, Cimino S, De Cobelli O, Maiorino F, Bove P, Crocerossa F, Cantiello F, D'Andrea D, Di Cosmo F, Porpiglia F, Ditonno P, Montanari E, Soria F, Gontero P, Liguori G, Trombetta C, Mantica G, Borghesi M, Terrone C, Del Giudice F, Sciarra A, Galosi A, Moschini M, Shariat SF, Di Nicola M, Minervini A, Ferro M, Cerruto MA, Schips L, Pagliarulo V, Antonelli A. Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium). *World J Urol* 2022; **40**: 2771-2779 [PMID: 36203101 DOI: 10.1007/s00345-022-04156-3]

20 **Wang X**, MacLennan GT, Zhang S, Montironi R, Lopez-Beltran A, Tan PH, Foster S, Baldridge LA, Cheng L. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. *Hum Pathol* 2009; **40**: 211-217 [PMID: 18799188 DOI: 10.1016/j.humpath.2008.07.003]

21 **Zhu S**, Yu C, Wang C, Ding G, Cheng S. Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation. *Front Oncol* 2022; **12**: 969106 [PMID: 36330483 DOI: 10.3389/fonc.2022.969106]

22 **Mohan BP**, Jayalakshmy PL, Letha V, Bhat S. Sarcomatoid Carcinoma of Renal Pelvis Involving Ureter and Renal Parenchyma with Heterologous Osteosarcomatous Differentiation: A Case Report and Review of Literature. *Iran J Pathol* 2018; **13**: 89-93 [PMID: 29731801]

23 **Lisa M**, Singh GR, Madhawi R, Kumar B, Imam ZS. Sarcomatoid Carcinoma of Renal Pelvis with Abundant Heterologous Osteosarcomatous Element: A Case Report. *J Clin Diagn Res* 2017; **11**: ED31-ED32 [PMID: 28892918 DOI: 10.7860/JCDR/2017/28312.10268]

24 **Cuadra-Urteaga JL**, Font A, Tapia G, Areal J, Taron M. Carcinosarcoma of the upper urinary tract with an aggressive angiosarcoma component. *Cancer Biol Ther* 2016; **17**: 233-236 [PMID: 26891233 DOI: 10.1080/15384047.2016.1139237]

25 **Fernández-Pello S**, Venta V, González I, Gil R, Menéndez CL. Pyonephrosis as a sign of sarcomatoid carcinoma of the renal pelvis. *World J Clin Cases* 2014; **2**: 215-218 [PMID: 24945010 DOI: 10.12998/wjcc.v2.i6.215]

26 **Chen GM**, Chen SW, Xia D, Li J, Yan S, Jin BY. Sarcomatoid carcinoma of the renal pelvis in duplex kidney. *Chin Med J (Engl)* 2011; **124**: 2074-2076 [PMID: 22088474]

27 **Mimura A**, Sakuma T, Furuta M, Tanigawa N, Takamizu R, Kawano K. Sarcomatoid collecting duct carcinoma of kidney diagnosed with urine and renal pelvic lavage cytology. *Diagn Cytopathol* 2010; **38**: 603-606 [PMID: 20014307 DOI: 10.1002/dc.21290]

28 **Thiel DD**, Igel TC, Wu KJ. Sarcomatoid carcinoma of transitional cell origin confined to renal pelvis. *Urology* 2006; **67**: 622.e9-622.11 [PMID: 16504263 DOI: 10.1016/j.urology.2005.09.026]

29 **Shimasaki N**, Inoue K, Nishigawa H, Kuroda N, Shuin T. Combined small cell carcinoma and sarcomatoid squamous cell carcinoma in the renal pelvis. *Int J Urol* 2005; **12**: 686-689 [PMID: 16045564 DOI: 10.1111/j.1442-2042.2005.01134.x]

30 **Acikalin MF**, Kabukcuoglu S, Can C. Sarcomatoid carcinoma of the renal pelvis with giant cell tumor-like features: case report with immunohistochemical findings. *Int J Urol* 2005; **12**: 199-203 [PMID: 15733116 DOI: 10.1111/j.1442-2042.2005.01002.x]

31 **Vermeulen P**, Hoekx L, Colpaert C, Wyndaele JJ, Van Marck E. Biphasic sarcomatoid carcinoma (carcinosarcoma) of the renal pelvis with heterologous chondrogenic differentiation. *Virchows Arch* 2000; **437**: 194-197 [PMID: 10993282 DOI: 10.1007/s004280000190]

32 **Sekido Y**, Satoh F, Usui Y, Tsutsumi Y. Sarcomatoid carcinoma of the renal pelvis: a case report. *Pathol Int* 2000; **50**: 562-567 [PMID: 10886741 DOI: 10.1046/j.1440-1827.2000.01079.x]

33 **Kandemir O**, Tatlişen A, Kontaş O, Orskiran G, Kahya HA. Sarcomatoid squamous cell carcinoma of the right renal pelvis with liver metastasis: case report. *J Urol* 1995; **153**: 1895-1896 [PMID: 7752344]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 30, 2023

**First decision:** September 20, 2023

**Article in press:** October 26, 2023

**Specialty type:** Urology and Nephrology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Cassell III AK, Liberia **S-Editor:** Lin C **L-Editor:** A **P-Editor:** Zhao S


**Figure Legends**




**Figure 1 Patient diagnosis and treatment process flowchart.**




**Figure 2** **Computed tomography scans.** A: Cross-section; B: Coronal-section.



**Figure 3 Unenhanced and enhanced magnetic resonance imaging.** A: T2 cross-section; B: T1 cross-section; C: T2 coronal-section; D: Enhanced magnetic resonance imaging (MRI) coronal-section; E: Enhanced MRI sagittal-section.



**Figure 4** **Gross morphology of the tumor and HE staining results.** A: Gross morphology; B-D: HE staining images at 40 × (B), 100 × (C), and 200 × (D).



**Figure 5 Immunohistochemical staining results.** A: 34β12; B: CKpan; C: GATA3; D: Ki67; E: P63; F: Vimentin. Magnification: 200 ×.

**Table 1 Gene analysis results**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Characteristics** | **Gene** | **Exon** | **Nucleic acid variation** | **Amino acid change** | **Abundance** |
| Gene name | *ELF* | Exon 4 | c.421G>C | p.E141Q | 9.45% |
| *LTK* | Exon 10 | c.1321A>G | p.M441V | 7.00% |
| *NOTCH2* | Exon 25 | c.4028A>G | p.Q1343R | 1.34% |
| *REL* | Exon 9 | c.947A>G | p.D316G | 7.17% |
| *ZFHX3* | Exon 9 | c.6643C>T | p.P2215S | 2.94% |

**Table 2 Previous case reports of renal pelvis sarcomatoid carcinoma**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **No** | **Ref.** | **Age/sex/side** | **Size** | **Prognosis** | **Subsequent treatment** |
| 1 | Chu *et al*[6], 2023 | 71/M/R | 6.3 × 4.6 cm | Survived over 1 yr | Chemotherapy |
| 2 | Rashid *et al*[11], 2018 | 70/M/R | 5.5 cm × 4.5 cm × 4.5 cm | NA | NA |
| 3 | Mohan *et al*[22], 2018 | 68/F/L | 10.0 cm × 4.5 cm × 3.0 cm | 10 m no recurrence | Non |
| 4 | Lisa *et al*[23], 2017 | 47/M/L | 7.0 cm × 5.0 cm × 4.5 cm | 1 mo recurrence; Died < 5 mo | Non |
| 5 | Kivlin *et al*[4], 2016 | 77/M/R | 10.0 cm × 10.0 cm × 10.0 cm | NA | Non |
| 6 | Cuadra-Urteaga *et al*[24], 2016 | 44/M/R | 6.0 cm × 6.5 cm × 7.5cm | T3aNxMx; Died 8 wk after surgery | Non |
| 7 | Tian *et al*[2], 2014 | 49/F/L | Approximately 2 cm in diameter | T1N0M0; 30-mo follow-up without recurrence | Non |
| 8 | Fernández-Pello *et al*[25], 2014 | 58/M/R | 15.0 cm × 9.0 cm × 7.0 cm | T4NxMx; 18 mo follow-up without recurrence | Non |
| 9 | Gill-Samra *et al*[9], 2012 | 76/F/R | NA | 2 mo recurrence after surgery | Non |
| 10 | Chen *et al*[26], 2011 | 77/M/L | 16.0 cm × 12.0 cm × 9.0 cm | Non-resurrence until the article published | Non |
| 11 | Mimura *et al*[27], 2010 | 66/M/L | 4.0 cm × 3.5 cm × 3.0 cm | Died 7 mo after surgery | Non |
| 12 | Masue *et al*[8], 2007 | 58/M/L | 3.5 cm × 2.3 cm × 2.5 cm | T3N0M1; 46 mo disease-free | Non |
| 13 | Thiel *et al*[28], 2006 | 61/M/L | 4.5 cm in diameter | 16 mo without recurrence or metastasis | Non |
| 14 | Shimasaki *et al*[29], 2005 | 61/F/R | 6.5 cm × 4.0 cm × 3.0 cm | 16 mo without recurrence or metastasis | Non |
| 15 | Acikalin *et al*[30], 2005 | 66/M/L | 2.5 cm in diameter | Died 7 mo after operation | Non |
| 16 | Vermeulen *et al*[31], 2000 | 77/M/R | 4.7 cm in diameter | 8 mo without recurrence or metastasis | Non |
| 17 | Sekido *et al*[32], 2000 | 72/M/R | 8.4 cm × 6.5 cm | 9 mo without recurrence or metastasis | Non |
| 18 | Kandemir *et al*[33], 1995 | 26/M/R | 12.0 cm × 8.0 cm × 7.0 cm | Died of septic shock 3 d after the operation | Non |

M: Male; F: Female; L: Left; R: Right; NA: Not mentioned.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**